Danaher Co. (NYSE:DHR) Shares Sold by Cullen Frost Bankers Inc.

Cullen Frost Bankers Inc. cut its position in shares of Danaher Co. (NYSE:DHR) by 1.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 152,018 shares of the conglomerate’s stock after selling 2,102 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Danaher were worth $35,168,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Wellington Management Group LLP increased its stake in shares of Danaher by 18.6% during the 3rd quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after purchasing an additional 3,905,449 shares in the last quarter. Northern Trust Corp lifted its holdings in Danaher by 1.7% in the 3rd quarter. Northern Trust Corp now owns 8,100,722 shares of the conglomerate’s stock valued at $2,009,789,000 after purchasing an additional 134,905 shares in the last quarter. Flossbach Von Storch AG grew its holdings in shares of Danaher by 1.8% during the fourth quarter. Flossbach Von Storch AG now owns 4,601,351 shares of the conglomerate’s stock worth $1,064,477,000 after buying an additional 82,672 shares in the last quarter. Fisher Asset Management LLC boosted its position in Danaher by 6.2% during the fourth quarter. Fisher Asset Management LLC now owns 4,227,108 shares of the conglomerate’s stock worth $977,900,000 after acquiring an additional 248,140 shares during the last quarter. Finally, Invesco Ltd. grew its stake in Danaher by 13.2% in the 3rd quarter. Invesco Ltd. now owns 4,070,455 shares of the conglomerate’s stock worth $1,009,880,000 after acquiring an additional 473,693 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Stock Up 0.6 %

Shares of NYSE:DHR traded up $1.45 during trading on Tuesday, hitting $248.85. The company’s stock had a trading volume of 1,683,401 shares, compared to its average volume of 2,744,101. Danaher Co. has a fifty-two week low of $182.09 and a fifty-two week high of $259.00. The stock’s 50-day moving average price is $248.27 and its two-hundred day moving average price is $233.19. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.51 and a current ratio of 1.85. The company has a market capitalization of $184.32 billion, a PE ratio of 42.18, a PEG ratio of 3.82 and a beta of 0.83.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.20. The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The firm’s quarterly revenue was down 2.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.36 earnings per share. As a group, sell-side analysts expect that Danaher Co. will post 7.63 EPS for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be issued a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.43%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the company. Raymond James upped their target price on Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. HSBC upgraded Danaher from a “hold” rating to a “buy” rating and upped their price objective for the stock from $250.00 to $280.00 in a report on Wednesday, April 17th. Robert W. Baird raised their price objective on Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a report on Wednesday, April 24th. TD Cowen boosted their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Six research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and a consensus price target of $267.31.

Insider Activity at Danaher

In other news, Director Walter G. Lohr sold 3,289 shares of the firm’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $251.15, for a total value of $826,032.35. Following the transaction, the director now directly owns 14,129 shares in the company, valued at approximately $3,548,498.35. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In related news, Director Alan G. Spoon sold 708 shares of Danaher stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the sale, the director now directly owns 116,202 shares in the company, valued at approximately $28,304,483.16. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Walter G. Lohr sold 3,289 shares of the company’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $251.15, for a total transaction of $826,032.35. Following the completion of the transaction, the director now owns 14,129 shares of the company’s stock, valued at approximately $3,548,498.35. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 103,984 shares of company stock valued at $25,997,094. Corporate insiders own 10.90% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.